Home › Companies › PRAXIS PRECISION MEDICINES INC. › 2024-2025
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and PRAXIS PRECISION MEDICINES INC.’s Form 8-K, filed June 27, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 26, 2025: 4 items on PRAXIS PRECISION MEDICINES INC.’s Form 8-K, filed June 27, 2025: 2 approved · 2 passed (calculated).
Significant dissent: 1 say-on-pay vote (60.7% support).
Notable dissent: 1 director (17.0% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore PRAXIS PRECISION MEDICINES INC. in the interactive database Compare manager voting policies
These tallies are PRAXIS PRECISION MEDICINES INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 27, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Jeffrey Chodakewitz, M.D. | 14,596,188 | -- | -- | 2,998,186 | 778,152 | 83% | Passed (calculated) | — |
| Elect Director: Merit Cudkowicz, M.D. | 17,499,300 | -- | -- | 95,074 | 778,152 | 99.5% | Passed (calculated) | — |
| 2. Ratification of Appointment of Ernst & Young LLP as the Company's Independent Registered Public Accounting Firm | 18,358,636 | 7,630 | 6,260 | -- | 0 | 99.9% | Approved | — |
| 3. Advisory Vote on Executive Compensation | 10,671,320 | 6,919,705 | 3,349 | -- | 778,152 | 61% | Approved | — |
Source: PRAXIS PRECISION MEDICINES INC., Form 8-K, filed with the SEC on June 27, 2025 — read the filing on EDGAR.
See voting trends for Health Care companies, 2024-2025: shareholder support by sector and by company size.
189 asset managers disclosed a vote on at least one PRAXIS PRECISION MEDICINES INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
83% Majority: yes · of votes cast
Description as filed by funds: To elect the Class II Directors to serve until the 2028 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified: Jeffrey Chodakewitz, M.D.
PRAXIS PRECISION MEDICINES INC.’s own tally for this item (“Elect Director: Jeffrey Chodakewitz, M.D.”): 14,596,188 for, 2,998,186 withheld, per its Form 8-K filed June 27, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 83% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 52 asset managers below reported 3,712,298 for, 477,120 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,053,731 | 0 | 0 | 0 | For |
| T. Rowe Price | 905,205 | 0 | 0 | 0 | For |
| BlackRock | 452,758 | 0 | 0 | 0 | For |
| Fidelity | 361,398 | 0 | 0 | 35,869 | Mixed |
| State Street | 276,907 | 0 | 0 | 353 | For |
| JANUS INVESTMENT FUND | 234,406 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 0 | 0 | 150,691 | Withhold |
| Charles Schwab | 142,945 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 0 | 0 | 0 | 113,704 | Withhold |
| Northern Trust | 0 | 0 | 0 | 62,824 | Withhold |
| Equitable | 35,437 | 0 | 0 | 18,040 | Mixed |
| DRIEHAUS MUTUAL FUNDS | 44,110 | 0 | 0 | 0 | For |
| TIAA | 43,460 | 0 | 0 | 0 | For |
| Brighthouse | 35,092 | 0 | 0 | 6,252 | Mixed |
| QUANTITATIVE MASTER SERIES LLC | 25,976 | 0 | 0 | 0 | For |
| Transamerica | 20,311 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 19,393 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 0 | 0 | 0 | 14,808 | Withhold |
| Lincoln Financial | 12,800 | 0 | 0 | 0 | For |
| John Hancock | 5,832 | 0 | 0 | 6,137 | Mixed |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 11,037 | Withhold |
| HUSSMAN INVESTMENT TRUST | 10,500 | 0 | 0 | 0 | For |
| Global X | 0 | 0 | 0 | 10,448 | Withhold |
| UBS | 0 | 0 | 0 | 10,400 | Withhold |
| Brinker Capital Destinations Trust | 10,256 | 0 | 0 | 0 | For |
Showing the 25 largest of 52 asset managers. All 52 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99.5% Majority: yes · of votes cast
Description as filed by funds: To elect the Class II Directors to serve until the 2028 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified: Merit Cudkowicz, M.D.
PRAXIS PRECISION MEDICINES INC.’s own tally for this item (“Elect Director: Merit Cudkowicz, M.D.”): 17,499,300 for, 95,074 withheld, per its Form 8-K filed June 27, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.5% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 52 asset managers below reported 4,150,190 for, 39,228 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,053,731 | 0 | 0 | 0 | For |
| T. Rowe Price | 905,205 | 0 | 0 | 0 | For |
| BlackRock | 452,758 | 0 | 0 | 0 | For |
| Fidelity | 361,398 | 0 | 0 | 35,869 | Mixed |
| State Street | 277,260 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 234,406 | 0 | 0 | 0 | For |
| Aberdeen | 150,691 | 0 | 0 | 0 | For |
| Charles Schwab | 142,945 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 113,704 | 0 | 0 | 0 | For |
| Northern Trust | 62,824 | 0 | 0 | 0 | For |
| Equitable | 53,477 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 44,110 | 0 | 0 | 0 | For |
| TIAA | 43,460 | 0 | 0 | 0 | For |
| Brighthouse | 41,344 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 25,976 | 0 | 0 | 0 | For |
| Transamerica | 20,311 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 19,393 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 14,808 | 0 | 0 | 0 | For |
| Lincoln Financial | 12,800 | 0 | 0 | 0 | For |
| John Hancock | 11,969 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 11,037 | 0 | 0 | 0 | For |
| HUSSMAN INVESTMENT TRUST | 10,500 | 0 | 0 | 0 | For |
| Global X | 10,448 | 0 | 0 | 0 | For |
| UBS | 10,400 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 10,256 | 0 | 0 | 0 | For |
Showing the 25 largest of 52 asset managers. All 52 are in the interactive database (link above).
Combines 9 wordings of this item as funds reported it.
61% Approved · of votes cast
Prior year: 70.8% for (June 5, 2024 meeting) ▼ 10.2 pts
Description as filed by funds: To approve, on an advisory (non- binding) basis, the compensation of the named executive officers as disclosed in the Company's proxy statement for the 2025 Annual Meeting of Stockholders pursuant to the applicable compensation disclosure rules of the SEC, including the compensation tables and narrative discussion.
PRAXIS PRECISION MEDICINES INC.’s own tally for this item (“3. Advisory Vote on Executive Compensation”): 10,671,320 for, 6,919,705 against — passed, per its Form 8-K filed June 27, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 3 – Advisory Vote on Executive Compensation The Company's stockholders approved, on an advisory (non-binding) basis, the compensation of the Company's named executive officers, with the votes cast as follows:”
Support: 61% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 0 | 1,053,731 | 0 | 0 | Against |
| T. Rowe Price | 0 | 905,205 | 0 | 0 | Against |
| BlackRock | 8,223 | 444,535 | 0 | 0 | Against |
| Fidelity | 0 | 397,267 | 0 | 0 | Against |
| State Street | 276,907 | 353 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 234,406 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 150,691 | 0 | 0 | Against |
| Charles Schwab | 0 | 142,945 | 0 | 0 | Against |
| FRANKLIN STRATEGIC SERIES | 0 | 113,704 | 0 | 0 | Against |
| Northern Trust | 0 | 62,824 | 0 | 0 | Against |
| Equitable | 0 | 53,477 | 0 | 0 | Against |
| DRIEHAUS MUTUAL FUNDS | 44,110 | 0 | 0 | 0 | For |
| TIAA | 0 | 43,460 | 0 | 0 | Against |
| Brighthouse | 0 | 41,344 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 0 | 25,976 | 0 | 0 | Against |
| Transamerica | 0 | 20,311 | 0 | 0 | Against |
| RBB FUND, INC. | 19,393 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 0 | 14,808 | 0 | 0 | Against |
| Lincoln Financial | 12,800 | 0 | 0 | 0 | For |
| John Hancock | 0 | 11,969 | 0 | 0 | Against |
| Direxion Shares ETF Trust | 0 | 11,037 | 0 | 0 | Against |
| HUSSMAN INVESTMENT TRUST | 0 | 10,500 | 0 | 0 | Against |
| Global X | 0 | 10,448 | 0 | 0 | Against |
| UBS | 0 | 10,400 | 0 | 0 | Against |
| Brinker Capital Destinations Trust | 10,256 | 0 | 0 | 0 | For |
Fund voting reports, all 53 managers: 611,860 for, 3,576,085 against, 1,670 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1,914,591 | 0 | 0 | 0 | For |
| Janus Henderson | 1,431,878 | 34,015 | 0 | 0 | For |
| Cormorant Asset Management, LP | 1,446,372 | 0 | 0 | 0 | For |
| Soleus Capital Management, L.P. | 1,249,740 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 1,205,913 | 0 | 0 | Against |
| PERCEPTIVE ADVISORS LLC | 1,093,950 | 0 | 0 | 0 | For |
| BAKER BROS. ADVISORS LP | 689,488 | 0 | 0 | 0 | For |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 686,931 | 0 | 0 | 0 | For |
| State Street | 579,274 | 7,372 | 0 | 0 | For |
| BlackRock | 20,732 | 469,796 | 0 | 0 | Against |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 403,082 | 0 | 0 | Against |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 397,994 | 0 | 0 | 0 | For |
| Point72 | 0 | 370,817 | 0 | 0 | Against |
| CIBC Asset Management Inc | 0 | 336,392 | 0 | 0 | Against |
| FRANKLIN ADVISERS INC | 0 | 314,103 | 0 | 0 | Against |
| VR Adviser, LLC | 244,858 | 0 | 0 | 0 | For |
| Verition Fund Management LLC | 0 | 199,642 | 0 | 0 | Against |
| 5AM Venture Management, LLC | 170,000 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 150,691 | 0 | 0 | Against |
| Charles Schwab | 0 | 142,945 | 0 | 0 | Against |
| Northern Trust | 0 | 128,510 | 0 | 0 | Against |
| PFM Health Sciences, LP | 0 | 126,025 | 0 | 0 | Against |
| Alyeska Investment Group, L.P. | 0 | 107,387 | 0 | 0 | Against |
| SILVERARC CAPITAL MANAGEMENT, LLC | 0 | 80,793 | 0 | 0 | Against |
| Ally Bridge Group (NY) LLC | 74,327 | 0 | 0 | 0 | For |
Institutional-manager reports, all 151 managers: 10,339,119 for, 4,779,464 against, 21 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Prior year: 99.9% for (June 5, 2024 meeting) ▲ 0.1 pts
Description as filed by funds: TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.
PRAXIS PRECISION MEDICINES INC.’s own tally for this item (“2. Ratification of Appointment of Ernst & Young LLP as the Company's Independent Registered Public Accounting Firm”): 18,358,636 for, 7,630 against — passed, per its Form 8-K filed June 27, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2 – Ratification of Appointment of Ernst & Young LLP as the Company's Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31…”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 53 asset managers below reported 4,187,945 for, 1,670 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,053,731 | 0 | 0 | 0 | For |
| T. Rowe Price | 905,205 | 0 | 0 | 0 | For |
| BlackRock | 452,758 | 0 | 0 | 0 | For |
| Fidelity | 397,267 | 0 | 0 | 0 | For |
| State Street | 277,260 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 234,406 | 0 | 0 | 0 | For |
| Aberdeen | 150,691 | 0 | 0 | 0 | For |
| Charles Schwab | 142,945 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 113,704 | 0 | 0 | 0 | For |
| Northern Trust | 62,824 | 0 | 0 | 0 | For |
| Equitable | 53,477 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 44,110 | 0 | 0 | 0 | For |
| TIAA | 43,460 | 0 | 0 | 0 | For |
| Brighthouse | 41,344 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 25,976 | 0 | 0 | 0 | For |
| Transamerica | 20,311 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 19,393 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 14,808 | 0 | 0 | 0 | For |
| Lincoln Financial | 12,800 | 0 | 0 | 0 | For |
| John Hancock | 11,969 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 11,037 | 0 | 0 | 0 | For |
| HUSSMAN INVESTMENT TRUST | 10,500 | 0 | 0 | 0 | For |
| Global X | 10,448 | 0 | 0 | 0 | For |
| UBS | 10,400 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 10,256 | 0 | 0 | 0 | For |
Showing the 25 largest of 53 asset managers. All 53 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 20,341,917 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 5.18% |
| 2 | T. Rowe Price | 4.45% |
| 3 | BlackRock | 2.23% |
| 4 | Fidelity | 1.95% |
| 5 | State Street | 1.36% |
| 6 | JANUS INVESTMENT FUND | 1.15% |
| 7 | Aberdeen | 0.74% |
| 8 | Charles Schwab | 0.70% |
| 9 | FRANKLIN STRATEGIC SERIES | 0.56% |
| 10 | Northern Trust | 0.31% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 9.41% |
| 2 | Janus Henderson | 7.21% |
| 3 | Cormorant Asset Management, LP | 7.11% |
| 4 | Soleus Capital Management, L.P. | 6.14% |
| 5 | T. Rowe Price | 5.93% |
| 6 | PERCEPTIVE ADVISORS LLC | 5.38% |
| 7 | BAKER BROS. ADVISORS LP | 3.39% |
| 8 | DEERFIELD MANAGEMENT COMPANY, L.P. | 3.38% |
| 9 | State Street | 2.88% |
| 10 | BlackRock | 2.41% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 2,763,859 | 13.59% | Schedule 13G, filed November 14, 2025 |
| ORBIS INVESTMENT MANAGEMENT LTD | 2,468,413 | 12.13% | Schedule 13G, filed May 15, 2026 |
| FMR LLC | 2,156,343 | 10.60% | Schedule 13G, filed May 6, 2026 |
| Perceptive Advisors LLC | 1,995,986 | 9.81% | Schedule 13G, filed February 17, 2026 |
| Entities affiliated with Perceptive Advisors | 1,829,735 | 8.99% | Proxy statement (DEF 14A), proxy filed April 30, 2025 |
| Baker Bros. Advisors LP | 1,753,198 | 8.62% | Schedule 13G, filed May 15, 2026 |
| BlackRock | 1,416,935 | 6.97% | Form 13F, quarter ended March 31, 2025 |
| Entities affiliated with Point72 | 1,248,236 | 6.14% | Proxy statement (DEF 14A), proxy filed April 30, 2025 |
| Morgan Stanley | 1,213,669 | 5.97% | Form 13F, quarter ended March 31, 2025 |
| Steven A. Cohen | 1,212,728 | 5.96% | Schedule 13G, filed May 15, 2025 |
Percentages above are of 20,341,917 shares outstanding, as reported by PRAXIS PRECISION MEDICINES INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At PRAXIS PRECISION MEDICINES INC.'s shareholder meeting held June 26, 2025, in the 2024-2025 proxy season, 189 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 776 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory (non- binding) basis, the compensation of the named executive… — PRAXIS PRECISION MEDICINES INC.'s filing reports the proposal as approved, with 61% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: PRAXIS PRECISION MEDICINES INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 27, 2025.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from PRAXIS PRECISION MEDICINES INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
PRAXIS PRECISION MEDICINES INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.
Proxy Votes Now, “PRAXIS PRECISION MEDICINES (PRAX) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/praxis-precision-medicines-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.